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Abstract 
Hypertension is a heterogeneous syndrome in need of improved subtyping using phenotypic and 
genetic measurements so that patients in different subtypes share similar pathophysiologic 
mechanisms and respond more uniformly to targeted treatments. Existing machine learning 
approaches often face challenges in integrating phenotype and genotype information and 
presenting to clinicians an interpretable model. We aim to provide informed patient stratification 
by introducing Hybrid Non-negative Matrix Factorization (HNMF) on phenotype and genotype 
matrices. HNMF simultaneously approximates the phenotypic and genetic matrices using 
different appropriate loss functions, and generates patient subtypes, phenotypic groups and 
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genetic groups. Unlike previous methods, HNMF approximates phenotypic matrix under 
Frobenius loss, and genetic matrix under Kullback-Leibler (KL) loss. We propose an alternating 
projected gradient method to solve the approximation problem. Simulation shows HNMF 
converges fast and accurately to the true factor matrices. On real-world clinical dataset, we used 
the patient factor matrix as features to predict main cardiac mechanistic outcomes. We compared 
HNMF with six different models using phenotype or genotype features alone, with or without 
NMF, or using joint NMF with only one type of loss. HNMF significantly outperforms all 
comparison models. HNMF also reveals intuitive phenotype-genotype interactions that 
characterize cardiac abnormalities.  
 
 
1.  Introduction 
 
Precision medicine aims to utilize information from multiple modalities—including phenotypic 
and genetic measurements—to develop an individualized and comprehensive view of a patient’s 
pathophysiologic progression, to identify unique disease subtypes, and to administer personalized 
therapies (Kohane, 2015). Existing efforts are often based on only a selected set of biomarkers. 
The rapid growth of phenotypic and genetic data for many common diseases poses technical 
challenges for subtyping them, due to the high dimensionality of data, diversity of data types, 
uncertainty and missing data. However, the rapid growth of multiple data modalities, when linked 
to the right patients, may provide a prismatic view of the underlying pathophysiology of these 
diseases and offers a basis for meaningful subtyping of these patients. 
Hypertension is an example of a complex, heterogeneous clinical syndrome characterized by 
elevated blood pressure. Although typically considered a single disease, primary hypertension 
(i.e., essential hypertension) is in fact a heterogeneous group of subtypes with varying etiologies 
and pathophysiology. This common form of hypertension is highly prevalent and is polygenic in 
nature. However, genetic studies of hypertension have focused primarily on analyzing single 
variants at a time and then ranking them in terms of significance, as has been done in several 
genome-wide association studies (see (Poulter, Prabhakaran, & Caulfield, 2015) for a review). 
However, it is more likely that genetic variants interact with each other to increase susceptibility 
to disease. Furthermore, genetic variants interact with phenotypic risk factors to further promote 
the development of diseases such as hypertension. With the growing availability of high 
throughput genotyping and phenotyping data (such as through NIH/NHLBI TOPMed program), 
the need for integrating both data modalities is becoming increasingly pressing. Thus, it is critical 
to develop a methodology to combine phenotypic and genetic data when clustering patients for the 
identification of novel subtypes of disease. Such work could help identify novel molecular and 
pathophysiological pathways of disease and also may identify subgroups of patients who are more 
homogeneous in their response to specific therapies.   
Major contributions of this paper are: 1) Aiming to provide informed patient stratification, we 
propose Hybrid Non-negative Matrix Factorization (HNMF) that approximates phenotype and 
genotype matrices using different appropriate loss functions, instead of single loss function in 
previous joint NMF methods. 2) We use simulation to show HNMF converges fast and accurately 
to true factor matrices, and we use a real-world clinical dataset to show HNMF-generated patient 
factor matrix is more effective in predicting indices of cardiac mechanics compared to multiple 
non-NMF, NMF and joint NMF based methods. 3)  We show that HNMF-generated group 
matrices lead to insights on phenotype-genotype interactions that characterize cardiac 
abnormalities. 
From the clinical perspective, there have been only a few previous studies that have examined 
the clustering of hypertensive patients. Katz et al. applied model-based clustering to a cohort of 
1,273 hypertensive individuals, using only phenotypic data as features (Katz et al., 2017). Study 
participants were clustered into 2 distinct groups that differed markedly in clinical characteristics, 
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cardiac structure/function, and indices of cardiac mechanics. Guo et al. (Guo et al., 2017) used K-
means clustering of phenotypic data (clinical and blood pressure characteristics) and found 4 
groups of interest. However, neither of these studies utilized genetic data, which could have 
provided an additional important dimension to the clustering of hypertension, particularly when 
combined with phenotypic data.  
From the method perspective, Non-negative Matrix Factorization (NMF) refers to the set of 
problems on approximating a non-negative matrix as the product of several non-negative 
matrices. The problem has become popular since Lee and Seung's Nature paper (D. D. Lee & 
Seung, 1999), where they form a nonnegative matrix by concatenating the set of pixel intensity 
vectors stretched from human facial images. After factorizing such matrix into the product of two 
matrices, they found that one matrix can be interpreted as the set of image basis with part based 
representation of human faces, and the other matrix is the coefficients if we were to reconstruct 
the face image from those bases. Because of the non-negativity constraints, NMF is not a convex 
problem and they developed a multiplicative update algorithm to obtain a stationary solution, with 
provable convergence of the algorithm (Daniel D Lee & Seung, 2001). 
Since then researchers have been working on NMF from various aspects. Ding and Simon (C. 
Ding, He, & Simon, 2005) showed that there is some equivalence between NMF and 
Kmeans/spectral clustering and claim NMF can be used for data clustering. Ding et al. (C. Ding, 
Li, Peng, & Park, 2006) further developed a t-NMF approach that can perform co-clustering on 
both matrix columns and rows. They also discussed the various NMF variants (C. H. Ding, Li, & 
Jordan, 2010). Dhillon et al. (Sra & Dhillon, 2006) extended NMF to the case when the matrix 
approximation loss is measured by Bregman divergence, which is a much more general loss with 
both Frobenius norm and KL divergence (which are discussed in (Daniel D Lee & Seung, 2001)) 
as its special cases. On the solution procedure aspect, multiplicative updates have been recognized 
for its slow convergence and poor quality. Lin (Lin, 2007) proposed a projected gradient approach 
for NMF. Kim and Park (J. Kim & Park, 2011) also proposed an active set type of method called 
principal block pivoting to solve the NMF problem. 
NMF is a highly effective unsupervised method to cluster similar patients (Hofree, Shen, 
Carter, Gross, & Ideker, 2013; Yuan Luo, Xin, Joshi, Celi, & Szolovits, 2016) and sample cell 
lines (Müller et al., 2008), and to identify subtypes of diseases (Collisson et al., 2011). 
Conventional NMF can only model either phenotypic measurements (e.g. using Frobenius loss) or 
genetic variants (e.g., using KL loss) but not both. Recent studies have investigated methods for 
joint matrix factorization, serving the purpose of meta-analysis (Wang, Zheng, & Zhao, 2014), 
multi-view clustering (Liu, Wang, Gao, & Han, 2013) or imposing multiple characterization of 
documents (H. Kim, Choo, Kim, Reddy, & Park, 2015). However, these methods focus on using 
Frobenius loss to measure approximation accuracy of multiple matrices, and cannot readily 
integrate phenotypic measurements and genetic variants where approximating the two matrices 
admit different types of loss functions. Gunasekar et al. (Gunasekar et al., 2016) proposed 
collective matrix factorization based on the Bregman divergence framework to integrate multi-
source EHR phenotyping data, implemented KL-divergence as matrix approximation loss and 
experimented on discrete diagnosis and medications data.  
In theory, both KL divergence and Frobenius loss are special cases of Bregman divergence, but 
care needs to be taken when materializing the theoretical framework to the concrete case of hybrid 
genotypic and continuous phenotypic data. Challenges include how to derive useful genetic 
variant information from terabytes of whole exome sequencing data, how to filter deleterious 
variants, how to properly implement HNMF with missing continuous data, etc. Our paper is one 
such concrete materialization to integrate phenotypic and genotypic information for patient 
subtyping. Addressing both the clinical and methodological challenges, we propose the model of 
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Hybrid Non-negative Matrix Factorization (HNMF) which models the approximations of 
phenotypic and genetic matrices under Frobenius loss and KL loss respectively. We develop an 
alternating project gradient descent method for optimizing the HNMF objective, and demonstrate 
its fast convergence and effectiveness in integrating both the phenotypic and genetic data using 
both simulated and real-world studies. 
 
 
2.  Materials and Methods 
 
We develop a hybrid matrix factorization method to integrate both phenotypic and genetic 
features. The model applies non-negative matrix factorization to discover groups of phenotypic 
variables and genetic variants simultaneously that collectively and interactively characterize the 
groups of the patients. The approximation error is measured using Frobenius loss for the 
phenotypic matrix, and KL loss for the genetic matrix; hence we name our algorithm the Hybrid 
Non-negative Matrix Factorization (HNMF).  
 
 
2.1   Workflow of the study 
 
We first outline the workflow of the study in Figure 1. This study considers two types of patient 
data: phenotypic measurements and genetic variants. 
    We first impute missing values in the phenotypic variables. For genetic variants, we first 
annotate the variants and then keep those variants that are likely gene disruptive (LGD). The pre-
processed phenotypic measurements and genetic variants are then used as input to our HNMF 
algorithm. The patient factor matrix is then used as the feature matrix to perform regression 
analysis to predict main cardiac mechanistic outcomes. We next explain each step in detail. 
 
 
 
 
Figure 1: Study workflow. HNMF stands for hybrid non-negative matrix factorization. LGD stands 
for likely gene disruptive. 
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2.2   Cohort construction and data collection 
 
Our cohort comes from the Hypertension Genetic Epidemiology Network (HyperGEN) study. 
HyperGEN, part of the NIH Family Blood Pressure Program, is a cross-sectional study consisting 
of individuals with hypertension, their siblings and offspring, and a random sample of 
normotensives, all recruited from 4 cities in the United States (Williams et al., 2000). We focus on 
the African American participants (660 total), for whom we have both the phenotypic data (e.g., 
vitals) and whole exome sequencing (WES) data. We used two measurements from the 
echocardiograms that are main reflectors of systolic (longitudinal strain) and diastolic (septal e' 
velocity) cardiac mechanics as outcome variables (Table 1) (Mitter, Shah, & Thomas, 2017; Mor-
Avi et al., 2011). As opposed to conventional cardiac function measures such as ejection fraction, 
indices of cardiac mechanics obtained by speckle-tracking echocardiography are more sensitive 
measures of intrinsic cardiomyocyte function (Shah et al., 2014). Furthermore, indices of cardiac 
mechanics are thought to be subclinical measures of myocardial dysfunction that occur during the 
transition from risk factors (e.g., hypertension, obesity, diabetes, renal disease) to overt heart 
failure (Selvaraj et al., 2016). WES identifies the variants found in the coding region of genes 
(exons). In order to accurately and consistently call variants from across all datasets, we adopt the 
GATK framework (DePristo et al., 2011) for a standardized processing of WES data. 
 
Table 1: Outcome variables reflecting cardiac mechanics 
Outcome Description 
Septal e' velocity 
Left ventricular early diastolic relaxation velocity, measured at the 
septal mitral annulus in the apical 4-chamber view. Lower values reflect 
slower left ventricular relaxation and worse diastolic function. 
Longitudinal 
strain 
Left ventricular longitudinal strain measured in the apical 4-chamber 
view, a marker of subendocardial longitudinal systolic function. Lower 
absolute values reflect worse systolic function. 
 
 
2.3   Imputation on phenotypic variables 
 
Biomedical, epidemiological and clinical data often contain missing values for test results, some 
due to issues during data acquisition and archiving, but others due to the fact that clinicians do not 
order certain tests based on patient-specific diagnostic and treatment course. The missing 
percentage of the phenotypic variables considered in our study ranges from 0% to 37%. We had 
our cardiologist colleagues pick rather inclusively 129 phenotypic variables that can characterize 
the hypertension risk and cardiac physiology of the patients. We are rather tolerant on missing rate 
in order to retain as many variables as possible. Nevertheless, only 13/129 (10%) of the 
phenotypic variables had missingness > 10%. Six of these variables with missingness > 10% 
(including those with missingness > 30%) were phenotypes related to mitral inflow, which 
characterize diastolic function. Given the importance of diastolic dysfunction (i.e., abnormal 
cardiac relaxation and/or reduced cardiac compliance) in the setting of hypertension, we chose to 
retain these variables because of their clinical importance. We use the Multivariate Imputation by 
Chained Equations (MICE) algorithm to perform the imputation. This approach assumes a 
conditional model for each variable to be imputed, with the other variables as possible predictors 
(van Buuren & Groothuis-Oudshoorn, 2011). The term chained equation comes from the adoption 
of a Gibbs sampler, which is an iterative Markov Chain Monte Carlo (MCMC) algorithm. 
Previous studies (e.g., (Y. Luo, Szolovits, Dighe, & Baron, 2016)) showed that even at the 
presence of high missing rate (over 50%), MICE imputation may still render clinically useful 
information to predict patient outcome due to redundant information in phenotypic variables.  
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2.4   Annotation-based variant filtration and LGD variant detection 
 
We next used the ANNOVAR toolkit (K. Wang, Li, & Hakonarson, 2010) to comprehensively 
annotate called variants with a wide array of information, including their hosting gene (using 
several gene models such as RefSeq, UCSC Known Gene, Gencode (Harrow et al., 2012)); the 
variant function; its predicted pathogenicity according to PolyPhen2 (Adzhubei, Jordan, & 
Sunyaev, 2013), SIFT (Kumar, Henikoff, & Ng, 2009), CADD (Kircher et al., 2014), and other 
meta predictors; its minor allele frequency among the 1000 Genomes populations and ExAC (Lek 
et al., 2016); and its phenotype associations according to ClinVar, and HGMD (Stenson et al., 
2012). 
To address issues of reference mis-annotation, we resort to the recent-ly released Exome 
Aggregation Consortium (ExAC) exome dataset (Lek et al., 2016), which aims to aggregate 
exome sequencing data from a wide range of large-scale sequencing projects including the cohorts 
of Myocardial Infarction Genetics Consortium, Swedish Schizophrenia & Bipolar Studies and The 
Cancer Genome Atlas (TCGA). We filter out those variants whose allele frequencies are observed 
to be over 90% among the 60,706 individuals aggregated by ExAC. We also apply a similar 90% 
filtering threshold on the alternate allele frequency in our cohort. We further focus on likely gene 
disruptive (LGD) variants, which include frame-shift insertion, frame-shift deletions, nonsense 
variants, and splice site alterations. We have 6430 gene features for our cohort, 660 subjects. We 
follow the common practice and exclude the genes that have very rare variants (<10 subjects) or 
very frequent variants (> 50% of the subjects), resulting in 1481 genes. We then follow the com-
mon approach of gene prioritization (Moreau & Tranchevent, 2012) and further select the genes 
that show significant difference between the two hypertension groups (patient taking 1 vs. 
multiple anti-hypertensive medications) by two-tailed binomial exact tests (Howell, 2012). 
Eventu-ally, 349 (110) genes are selected for our cohort with p-value of binomial test less than 0.1 
(0.01). Each entry of our genetic matrix specifies how many variants a patient has on that gene. 
 
 
2.5   Hybrid NMF 
 
We propose the hybrid NMF (HNMF) model that integrates both pheno-typic and genetic 
measurements of patients. The phenotypic measure-ments we consider are continuous values, 
hence we use Gaussian distri-bution to model the approximation error. The genetic measurements 
are counts of the genetic variants that happen to a particular gene, thus we use Poisson distribution 
to model the variant count. A schematic view of our HNMF model is shown in Figure 2. 
 
Table 2: Notations. 
Variable Description 
𝑛 number of patients 
𝑚𝑝 number of phenotypes 
𝑚𝑔 number of genotypes 
𝑘 number of patient groups 
𝑋𝑝 ∈ 𝑅
𝑛×𝑚𝑝  patient by phenotype matrix, continuous value 
𝑋𝑔 ∈ 𝑅
𝑛×𝑚𝑔 patient by genotype matrix, count value 
𝐹 ∈ 𝑅𝑘×𝑛 patient group assignment matrix 
𝐺𝑝 ∈ 𝑅
𝑘×𝑚𝑝 phenotype group assignment matrix 
𝐺𝑔 ∈ 𝑅
𝑘×𝑚𝑔 genotype group assignment matrix 
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Figure 2: Hybrid Non-negative Matrix Factorization model. In the figure, 𝑋𝑝 is the patient-by-
phenotype-measurement matrix. 𝑋𝑔 is the patient-by-genetic-variant matrix. 𝐹 is the patient factor 
matrix specifying patient groups. 𝐺𝑝 is the phenotype factor matrix specifying groups of 
phenotypic measurements. 𝐺𝑔 is the genetic factor matrix specifying groups of genetic 
measurements. 
 
Our goal is to maximize the joint likelihood of the two approximations. Let the variables be 
defined as in Table 2, we establish the following constrained optimization problem. 
max  𝜆𝑙𝑜𝑔 𝑃(𝑋𝑔|𝐹, 𝐺𝑔) + 𝑙𝑜𝑔𝑃(𝑋𝑝|𝐹, 𝐺𝑝) 
𝑠𝑡. 𝐹 ≥ 0, 𝐺𝑝 ≥ 0, 𝐺𝑔 ≥ 0 
( 1 ) 
where 𝜆 indicates the trade-off between the phenotypic approximation and genetic approximation 
(𝜆 = 1 for our experiment), and the log likelihood functions are defined as follows. 
log 𝑃(𝑋𝑝|𝐹, 𝐺𝑝) = −
1
2𝛿2
∑ (𝑋𝑝𝑖𝑗 − ∑ 𝐹𝑢𝑖𝐺𝑝𝑢𝑗
𝑢
)
2
𝑖𝑗
+ 𝐶1 ( 2 ) 
log 𝑃(𝑋𝑔|𝐹, 𝐺𝑔) = ∑ (𝑋𝑔𝑖𝑗 log (∑ 𝐹𝑢𝑖𝐺𝑔𝑢𝑗
𝑢
) − ∑ 𝐹𝑢𝑖𝐺𝑔𝑢𝑗
𝑢
) + 𝐶2
𝑖𝑗
 ( 3 ) 
By minimizing the negative log likelihood, we arrive at the following objective function. 
  min ℒ(𝐹, 𝐺𝑝, 𝐺𝑔) = ∑ [
𝜆
2
(𝑋𝑝𝑖𝑗 − ?̂?𝑝𝑖𝑗)
2
+ ?̂?𝑔𝑖𝑗 − 𝑋𝑔𝑖𝑗 log (?̂?𝑔𝑖𝑗)]𝑖𝑗  
𝑠𝑡. 𝐹 ≥ 0, 𝐺𝑝 ≥ 0, 𝐺𝑔 ≥ 0 
 ( 4 ) 
where ?̂?𝑝𝑖𝑗 =
∑ 𝐹𝑢𝑖𝐺𝑝𝑢𝑗𝑢  and ?̂?𝑔𝑖𝑗 =
∑ 𝐹𝑢𝑖𝐺𝑔𝑢𝑗𝑢  Writing ℒ in the matrix form, we have  
ℒ(𝐹, 𝐺𝑝, 𝐺𝑔) = ∑ [
𝜆
2
‖𝑋𝑝 − ?̂?𝑝‖𝐹
2
+ ?̂?𝑔 − 𝑋𝑔 log(?̂?𝑔)]
𝑖𝑗
 ( 5 ) 
where ?̂?𝑝 = 𝐹
𝑇𝐺𝑝 and ?̂?𝑔 = 𝐹
𝑇𝐺𝑔. We can use the following alternating projected gradient 
descent procedure to solve the objective and establish the stopping criteria that the partial 
gradients should be small enough or all factor matrix updates cannot produce a feasible direction 
along which the objective function decreases (let Ƥ+(⋅) denote the non-negative projector): 
P
a
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x 
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P
a
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𝐹𝑡+1 =  Ƥ+ [𝐹
𝑡 − ɳ𝐹
𝑡 ∇Fℒ(𝐹, 𝐺𝑝
𝑡 , 𝐺𝑔
𝑡)|𝐹=𝐹𝑡]  ( 6 ) 
𝐺𝑝
𝑡+1 =  Ƥ+  [𝐺𝑝
𝑡 − ɳ𝐺𝑝
𝑡 ∇Gpℒ(𝐹
𝑡+1, 𝐺𝑝, 𝐺𝑔
𝑡)|𝐺𝑝=𝐺𝑝𝑡 ]  ( 7 ) 
𝐺𝑔
𝑡+1 =  Ƥ+  [𝐺𝑔
𝑡 − ɳ𝐺𝑔
𝑡 ∇Ggℒ(𝐹
𝑡+1, 𝐺𝑝
𝑡+1, 𝐺𝑔)|𝐺𝑔=𝐺𝑔𝑡 ] ( 8 ) 
These equations take turns in optimizing each factor matrix while keeping the other two fixed. 
We next present the partial gradients with respect to each of the three factor matrices. For 
phenotype group matrix 𝐺𝑝, we have 
∇𝐺𝑝ℒ(𝐹, 𝐺𝑝, 𝐺𝑔) = 𝜆(𝐹𝐹
𝑇𝐺𝑝 − 𝐹𝑋𝑝) ( 9 ) 
Let ?̂?𝑔 = 𝐹
𝑇𝐺𝑔, and ?̃?𝑔𝑖𝑗 = 𝑋𝑔𝑖𝑗/?̂?𝑔𝑖𝑗, for genotype group matrix 𝐺𝑔, we have  
𝛻𝐺𝑔ℒ(𝐹, 𝐺𝑝, 𝐺𝑔) = 𝐹(𝐸𝐺 − ?̃?𝑔) ( 10 ) 
where 𝐸𝐺 ∈ 𝑅
𝑛×𝑚𝑔 is an all-one matrix. For the patient group matrix 𝐹, we have 
𝛻𝐹ℒ(𝐹, 𝐺𝑃 , 𝐺𝑔) = 𝜆(−𝐺𝑝𝑋𝑝
𝑇 + 𝐺𝑝𝐺𝑝
𝑇𝐹) + 𝐺𝑔(𝐸𝐹 − ?̃?𝑔
𝑇) ( 11 ) 
    With those gradients, we can adopt an alternating projected gradient descent procedure to solve 
the hybrid matrix factorization problem. This is an iterative procedure, at each iteration, the 
algorithm optimizes the objective with one specific group of variables with all other variables 
fixed. The optimization procedure used at each iteration will be projected gradient descent. In 
order to determine the step size at each gradient descent step, we use the Armijo rule as a sub-
procedure which looks for the largest 𝜂 (step size) that satisfies the following sufficient decrease 
condition. Let 𝛩, 𝛩𝑛𝑒𝑤 denote the parameters (e.g., 𝐹, 𝐺𝑔 and 𝐺𝑝) before and after each iteration 
respectively, and 𝛿 ∈ (0,1) be a predefined number. General sufficient decrease condition can be 
written as   
ℒ(𝛩𝑛𝑒𝑤) − ℒ(𝛩) ≤ 𝛿𝑡𝑟(𝛻𝛩ℒ(𝛩)(𝛩
𝑛𝑒𝑤 − 𝛩)𝑇) ( 12 ) 
If ℒ is a quadratic form of 𝛩, we have a special fast-to-check sufficient decrease condition as 
Formula (13) (Lin, 2007). The algorithm for projected gradient descent with Armijo rule can be 
outlined as Algorithm 1. 
(1 − 𝛿)𝑡𝑟(𝛻𝛩ℒ(𝛩)(𝛩
𝑛𝑒𝑤 − 𝛩)𝑇) +
1
2
𝑡𝑟((𝛩𝑛𝑒𝑤 − 𝛩)𝛻𝛩
2ℒ(𝛩)(𝛩𝑛𝑒𝑤 − 𝛩)𝑇) ≤ 0 ( 13 ) 
 
Algorithm 1 Projected Gradient Descent with Armijo Rule 
1: Initialize Θ. Set 𝜂 = 1 
2: for 𝑖 = 1 to 𝑘 do 
3:     if 𝜂 satisfies Eq. ( 13 ) (or ( 12 ) if quadratic) then 
4:     Repeatedly increase 𝜂 as 𝜂 ← 𝜂/𝜌 until either 𝜌 does not satisfy Eq. ( 13 ) (or ( 12 ) 
if          quadratic) or Θ(𝜂/𝜌) = Θ 
5:     else 
6:         Repeatedly decrease 𝜂 as 𝜂 ← 𝜌𝜂 until 𝜂 satisfy Eq. ( 13 ) (or ( 12 ) if quadratic) 
7:     end if 
8:     Set Θ𝑛𝑒𝑤 = max (0, Θ − 𝜂∇Θℒ(Θ)) 
9: end for 
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2.6   Feature group discovery using HNMF 
 
In HNMF, the row vectors in the phenotype factor matrix 𝐺𝑝 and in the genetic factor matrix 𝐺𝑔 
specify the grouping of phenotypic measurements and genetic variants respectively. Such 
groupings can be viewed as mixtures of phenotypic (or genetic) features, as they allow sharing of 
these features among different groups as specified by its fractional weights across groups. The 
motivation is to identify paired phenotypic group and genetic group that together characterize 
pathophysiologic underpinnings. The approximated phenotypic matrix can be viewed as rank-one 
sum of outer-product of patient group (e.g., [𝐹𝑇]⋅5, 5th column of the patient group matrix) and 
phenotypic group (e.g., [𝐺𝑝]5⋅, 5th row of the phenotypic group matrix). Similar argument holds 
for genetic group matrix. Thus the patient group (e.g., [𝐹𝑇]⋅5) bridges the corresponding 
phenotypic group (e.g., [𝐺𝑝]5⋅) and genetic group (e.g., [𝐺𝑔]5⋅). We used the patient group matrix 
𝐹𝑇 as the instance-feature matrix in Ridge regression, and identify a column with maximum 
coefficient (e.g., [𝐹𝑇]⋅5). We selected the corresponding phenotypic and genetic groups (e.g., 
[𝐺𝑝]5⋅ and [𝐺𝑔]5⋅), which are paired through the shared patient group (e.g., 
[𝐹𝑇]⋅5) and provide 
interpretation advantage. Using the trained regression model, we rank the patient groups by their 
regression coefficients and focus on the top patient groups (and associated phenotypic and genetic 
groups) that are associated with large effect size.  
 
 
2.7   Evaluating the groups discovered by HNMF 
 
Because there is no innate way (except for simulation) to determine whether the groupings of 
phenotypic measurements and genetic variants discovered by HNMF are good or poor, we 
evaluate their utility as features, abstracted from the base data, in a prediction model. We assume 
that good features will improve prediction and will give us some insights into which phenotypic 
and genetic patterns are indicative of patient cardiac mechanic abnormality. We use the 
phenotypic and genetic data for participants from the Hypertension Genetic Epidemiology 
Network (HyperGEN) study. We take a subset of the African American patients who are 
hypertensive, and for whom we have both phenotypic and genetic data available at large scale. 
We predict the numeric values of the cardiac mechanic variables as outcomes (listed in Table 1). 
For each outcome variable, we randomly split these patients into a 7:3 train and held-out test 
dataset, and repeat the random initializations of HNMF and other NMF based comparison models 
50 times in order to improve the statistical robustness of the results. 
    To evaluate the effectiveness of HNMF in abstracting raw data into more predictive features, 
we use the patient factor matrix 𝐹 to train a Ridge regression model. We chose Ridge regression 
over alternatives such as support vector regression or random forest regression for its capability to 
generate deterministic weights for individual features. We match the groups in the phenotypic 
factor matrix and genetic factor matrix according to their row indices, and link them to the 
corresponding row in the patient factor matrix 𝐹. Linear regression then provides a convenient 
way to directly assess phenotypic and genetic group contribution. 
 
 
3.  Results 
 
In this section, we first evaluate the algorithmic performance using a simulated dataset where the 
actual factor matrices are known. Then, we evaluate the hybrid matrix factorization performance 
using the HyperGEN dataset. 
 
 
3.1   Simulation 
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We first analyze simulated data where the underlying factor matrices are known. Specifically, we 
consider a 20 × 10 𝑋𝑝 matrix and a 20 × 100 𝑋𝑔 matrix with the true number of factors being 3. 
That is, they are generated by a  3 × 20 𝐹 matrix, a 3 × 10 𝐺𝑝 matrix, and a 3 × 100 𝐺𝑔 matrix. 
We first sample the 𝐹, 𝐺𝑝, and 𝐺𝑔 matrices. We then generate the 𝑋𝑝 matrix by adding an error 
term 𝜖𝑝 on top of 𝐹
𝑇𝐺𝑝 where 𝜖𝑝 adopts standard normal distribution. Next we generate the 𝑋𝑔 
matrix by sampling according to Poisson distribution with the parameter set to 𝐹𝑇𝐺𝑔.  
    In order to evaluate the similarity between the factorized matrix and its true counterpart, we use 
the following similarity score: 
𝑠𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦(𝐴, 𝐵) =
𝑡𝑟(𝐴𝑇𝐵)
√𝑡𝑟(𝐴𝑇𝐴)√𝑡𝑟(𝐵𝑇𝐵)
 ( 14 ) 
where 𝑡𝑟(⋅) is trace and 𝑡𝑟(𝐴𝑇𝐵) can be considered as matrix inner product. This similarity score 
is essentially the cosine similarity, which quantifies the closeness between the computed solution 
and the actual factor matrix and provides a single number between 0 and 1 (Chi & Kolda, 2012). 
The simulation results are shown in Figure 3(a) where the similarity score is plotted as a function 
of maximum number of iterations for sub-procedures (optimizing 𝐹, 𝐺𝑝, 𝐺𝑔 one at a time while 
fixing the other two, using the Armijo rule), which represents the closeness to the sub-problem 
optima. Figure 3 shows that as we have extra sub-procedure iterations, the similarity scores first 
rise and then plateau quickly. We can also see that the similarity between the true factor matrices 
and those recovered by HNMF quickly reaches to an accurate level (>0.9). Figure 3(b) shows the 
convergence speed of the proposed alternating projected gradient descent method with the number 
of iterations for sub-procedures set to 100. We can see that both loss functions (Frobenius loss for 
phenotype matrix and KL loss for genotype matrix) quickly decrease within a few iterations. In 
fact, for our simulation, the stopping criteria is usually met in less than 50 iterations. 
 
  
Figure 3: Simulation results on a hybrid matrix factorization problem with rank 3. (a) Similarity 
score as a function of number of iterations for sub-procedures (b) Decreasing trend of loss 
functions for phenotype (Frobenius loss) and genotype matrix (KL loss) approximations during 
HNMF. 
 
 
3.2   Application on cardiac mechanics 
 
We then evaluate HNMF on its effectiveness of abstracting raw data into more predictive features. 
Using the 2 indices of cardiac mechanics listed in Table 1 as the outcome and the patient factor 
matrix F as the predictors, we train a Ridge regression model. We evaluate the root-mean-square 
error (RMSE) of our model on the held-out test set, and compare it against two baselines: (b1) 
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Using only genetic variants as regression features; (b2) Using only phenotypic measurements as 
regression features. We also established four comparison models as follows: (c1) Using only the 
genetic groups as regression features by applying NMF on the genetic variant matrix only; (c2) 
Using only the phenotypic groups as regression features by applying NMF on the phenotypic 
measurement matrix only; (c3) Using joint matrix factorization but use KL loss for both matrices; 
(c4) Using joint NMF but use Frobenius loss for both matrices.  
 
 
(a) 
 
 
(b) 
 
Figure 4: RMSE with 95% confidence interval for HNMF and comparison methods on the held-
out test data. gNMF – using genotype factor matrix as features; pNMF –phenotype factor matrix 
as features; hNMF –hybrid factor matrix as features; jNMF(KL) – joint matrix factorization using 
KL loss; jNMF(Fro) – joint matrix factorization using Frobenius loss.  
Integrating Hypertension Phenotype and Genotype with Hybrid Non-negative Matrix Factorization 
 
 
 
 
We follow Ho et al. (Ho, Ghosh, & Sun, 2014) on the evaluation procedure in that we vary the 
group number k from the smallest 2 to where the evaluation metric plateaus and show that across 
the spectrum HNMF outperforms multiple separate and joint NMF comparison models. The 
baseline RMSE performances are: 1.25 and 3.88 for geno-baseline on septal e’ velocity and 
longitudinal strain respectively, 1.20 and 3.55 for pheno-baseline respectively. The RMSE 
performance results of HNMF and comparison models are shown in Figure 4.  Comparing all the 
factorization models and non-factorization models, we can see that using factor matrices as 
features results in significant improvement (smaller RMSE) over using phenotypic measurements 
and genetic variants directly as features. Phenotype-only factor matrices often show better 
regression accuracy than genotype-only factor matrices, likely due to that fact that genetic raw 
matrix is much sparser than the phenotypic raw matrix. The HNMF factor matrix for regression 
also significantly outperforms all comparison models including genotype-only or phenotype-only 
factor matrix for regression, as well as the two joint NMF model results using either KL loss or 
Frobenius loss for both matrices. This suggests that HNMF can effectively integrate the 
phenotype and genotype features to predict cardiac mechanics outcomes. 
 
 
3.3   Sensitivity analysis 
 
When performing annotation-based genetic variant filtration, we select the genes that show 
significant difference in number of LGD variants between the two hypertension groups (patient 
taking 1 vs. multiple anti-hypertensive medications) by two-tailed binomial exact tests. Using a p-
value threshold of being less than 0.01 produces 110 genes for our cohort. This is a relatively 
stringent threshold and in this section we perform sensitivity analysis by varying the p-value 
threshold and including 0.05 and 0.1.  With these p-value thresholds, we include considerably 
more genes into consideration: 239 genes for 0.05 as threshold and 349 genes for 0.1 as threshold. 
The genotype baseline RMSEs are 4.87 (4.63) for longitudinal strain and 1.56 (1.50) for septal e’ 
velocity under p-value threshold 0.1 (0.05). Fig S1 (see Appendix B) shows the results of the 
sensitivity analysis in comparison with Figure 4. Comparing these figures, it is easy to see that 
under all p-value thresholds, HNMF consistently outperforms all baselines and NMF comparison 
models including pheno- and geno- separate NMF models and joint NMF models with KL or 
Frobenius losses. On the other hand, as one tightens the p-value threshold, the plateau region 
becomes wider, suggesting that the regression performance is less sensitive as the group number 
varies in the plateau region. Thus in the following phenotype and genotype group analysis, we 
chose p-value threshold of 0.01. Another reason is that with a stricter p-value threshold, we are 
more confident that selected genes are likely implicated in the pathogenesis of abnormal cardiac 
mechanics. We also note that with large enough patient cohort size, techniques such as cross-
validations can be used to accurately determine the optimal group number.  The larger the patient 
cohort size, the more effective cross-validation is, under more relaxed filtering criteria that result 
in more genes to consider. 
 
 
4.  Discussion 
 
Using the method in the feature group discovery section, we identified the top phenotypic and 
genetic groups that are associated with worse cardiac mechanics. Due to space limitation, we only 
show the top phenotypic and genetics groups associated with lower values of septal e’ velocity 
and longitudinal strain, as listed in Table 3. The phenotypic groups can help us identify variables 
that are correlated with abnormal cardiac mechanics. The associated genetic group consists of 
genes that potentially mediate the corresponding multi-variable phenotypic abnormality. They 
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collectively indicate problematic multi-factor genotype and phenotype interaction and attribute 
such interaction to a specific patient group (in F), thus can more comprehensively and precisely 
characterize and stratify these patients in an evidence-driven fashion. 
More specifically, the echocardiographic septal e' velocity is one of several variables used 
during the assessment of diastolic dysfunction. In general lower septal e' values are reflective of a 
higher degree of diastolic dysfunction, which is associated with the development of heart failure 
and/or adverse cardiovascular outcomes (Mitter et al., 2017). In septal-e' phenotype group, 
preserved (higher) left ventricular ejection fraction is often present in patients with diastolic 
dysfunction, other variables are associated with the development of diastolic dysfunction, 
including abnormal sodium, calcium, and albumin levels, and abnormal left ventricular wall 
thickness during diastole. In the septal-e’ gene group, TPM2 shows strong susceptibility to 
variants that lead to cardiomyopathies and IDI2 to chronic kidney disease (comorbidity and risk 
factor for cardiovascular disease). NPR2 is linked to cardiac conduction. GPRC6A is responsible 
for calcium sensing that affects L-type calcium channel and is critical to cardiac cell function 
(Mackenzie et al., 2005). MSMP is involved in resting heart rate modulation. For longitudinal 
strain, lower values suggest worse longitudinal systolic function of the subendocardium (inner 
layer of the heart), thus worse cardiac mechanics (Shah et al., 2014). In longitudinal strain 
phenotype group, besides abnormal sodium, calcium and albumin levels, both higher waist/hip 
ratio and faster sitting heart rate have a known association with the development of heart failure 
(Bui, Horwich, & Fonarow, 2011). In the longitudinal strain gene group, COX6B2 is in the 
cardiac muscle contraction pathway, CLDN5 is expressed in heart muscle, other genes also show 
strong susceptibility to variants that lead to cardiomyopathies (TPM2), other cardiovascular 
diseases (BMP4), and obesity as comorbidity (PAX5). 
 
Table 3: Top phenotypic and genetic groups (and their representative components) associated 
with lower values of septal e’ velocity and global longitudinal strain (worse cardiac 
mechanics). Paired phenotypic group and genetic group are linked by patient group. 
Septal e’: Top Phenotype Group Top Gene Group 
Sodium 
Calcium 
Albumin 
Left ventricular ejection fraction  
Relative wall thickness 
GPRC6A 
MSMP 
NPR2 
IDI2 
TPM2 
GLS: Top Phenotype Group Top Gene Group 
Sodium 
Calcium 
Albumin 
waist/hip ratio 
sitting heart rate 
COX6B2 
PAX5 
BMP4 
TPM2 
CLDN5 
 
 
To sum, we proposed a novel Hybrid Non-negative Matrix Factorization (HNMF) algorithm 
that integrates both phenotypic measurements and genetic variants as features in order to subtype 
patients. HNMF models the approximation error for the phenotypic matrix using Gaussian 
distribution, and models the variant count for the genetic matrix using Poisson distribution. The 
objective function is the negative log-likelihood of the data given parameters. We developed an 
alternating projected gradient descent method to solve the approximation problem. Using the 
simulated dataset, we demonstrated that HNMF has fast convergence and high accuracy when 
approximating the true factor matrices. Using the real-world HyperGEN dataset, we demonstrated 
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the effectiveness of HNMF in integrating both the phenotypic and genetic features to derive 
informative patient subgroupings. We used the patient factor matrix as features to predict the 
cardiac mechanics outcome variables. We compared HNMF with six different models using 
phenotype or genotype features directly, using NMF on these features separately, and using joint 
matrix factorization but with only one type of loss function. HNMF significantly outperforms all 
comparison models. Analyzing the identified phenotype and genotype groups reveals intuitive 
phenotype-genotype interactions that characterize cardiac abnormality. For future study, we plan 
to extend HNMF to consider prior medical knowledge (e.g., known phenotypic and genotypic 
characteristics associated with heart failure) in guiding the generation of the factor matrices for 
better patient stratification. We also plan to extend HNMF to a tri-factorization model that allows 
for different group numbers in patient, genotype and phenotype factor matrices, in order to benefit 
HNMF with more flexibility to handle heterogeneous and distinct modality of data sources. We 
plan to model the genetic matrix approximation using zero-inflated Poisson distribution, as genetic 
matrix is sparse. We also plan to relax LGD criteria to include more genetic variants and obtain 
Whole Genome Sequencing data to systematically capture potential regulatory variants. 
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Appendix A. 
 
Derivation of the partial gradients 
∇𝐺𝑝ℒ(𝐹, 𝐺𝑝, 𝐺𝑔) = 𝛻𝐺𝑝 [‖𝑋𝑝 − 𝐹
𝑇𝐺𝑝‖𝐹
2
+ 𝐶] = 𝛻𝐺𝑝 [𝑡𝑟 ((𝑋𝑝 − 𝐹
𝑇𝐺𝑝)
𝑇
(𝑋𝑝 − 𝐹
𝑇𝐺𝑝)) + 𝐶]
= ∇𝐺𝑝[𝑡𝑟(−2𝑋𝑝
𝑇𝐹𝑇𝐺𝑝 + 𝐺𝑝
𝑇𝐹𝐹𝑇𝐺𝑝) + 𝐶] = 𝜆(𝐹𝐹
𝑇𝐺𝑝 − 𝐹𝑋𝑝) 
 
∇𝐺𝑔ℒ(𝐹, 𝐺𝑝, 𝐺𝑔)|𝑎𝑏
= ∇𝐺𝑔 [∑ (∑ 𝐹𝑢𝑖𝐺𝑔𝑢𝑗 − 𝑋𝑔𝑖𝑗 log (∑ 𝐹𝑢𝑖𝐺𝑔𝑢𝑗
𝑢
)
𝑢
)
𝑖𝑗
+ 𝐶]|
𝑎𝑏
 
 
Let ?̂?𝑔 = 𝐹
𝑇𝐺𝑔, then 
∇𝐺𝑔ℒ(𝐹, 𝐺𝑝, 𝐺𝑔)|𝑎𝑏
= ∑ (
𝜕?̂?𝑔𝑖𝑗
𝜕𝐺𝑔𝑎𝑏
−
𝑋𝑔𝑖𝑗
?̂?𝑔𝑖𝑗
𝜕?̂?𝑔𝑖𝑗
𝜕𝐺𝑔𝑎𝑏
)
𝑖𝑗
 
We know 
𝜕?̂?𝑔𝑖𝑗
𝜕𝐺𝑔𝑎𝑏
= 𝐹𝑎𝑖 
 
When 𝑗 = 𝑏, let ?̃?𝑔𝑖𝑗 = 𝑋𝑔𝑖𝑗/?̂?𝑔𝑖𝑗, for genotype group matrix 𝐺𝑔, we have  
∇𝐺𝑔ℒ(𝐹, 𝐺𝑝, 𝐺𝑔)|𝑎𝑏
= ∑(𝐹𝑎𝑖 − ?̃?𝑔𝑖𝑏𝐹𝑎𝑖)
𝑖
= (𝐹1)𝑎 − (𝐹?̃?𝑔)𝑎𝑏 
So 𝛻𝐺𝑔ℒ(𝐹, 𝐺𝑝, 𝐺𝑔) = 𝐹(𝐸𝐺 − ?̃?𝑔), where 𝐸𝐺 ∈ 𝑅
𝑛×𝑚𝑔 is an all-one matrix.  
Now let’s compute the gradient with respect to 𝐹, which includes two parts 
∇𝐹‖𝑋𝑝 − 𝐹
𝑇𝐺𝑝‖𝐹
2
= 2(−𝐺𝑝𝑋𝑝
𝑇 + 𝐺𝑝𝐺𝑝
𝑇𝐹) 
∑ (
𝜕?̂?𝑔𝑖𝑗
𝜕𝐹𝑎𝑏
−
𝑋𝑔𝑖𝑗
?̂?𝑔𝑖𝑗
𝜕?̂?𝑔𝑖𝑗
𝜕𝐹𝑎𝑏
) =
𝑖𝑗
(𝐺𝑔1)𝑎 − (𝐺𝑔?̃?𝑔
𝑇
)
𝑎𝑏
 
Therefore, we have  
𝛻𝐹ℒ(𝐹, 𝐺𝑃 , 𝐺𝑔) = 𝜆(−𝐺𝑝𝑋𝑝
𝑇 + 𝐺𝑝𝐺𝑝
𝑇𝐹) + 𝐺𝑔 (𝐸𝐹 − ?̃?𝑔
𝑇
) 
 
where 𝐸𝐹 ∈ 𝑅
𝑚𝑔×𝑛 is an all-one matrix. 
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Appendix B. 
 
(a) (c)
(b) (d) 
Fig.  S1. Sensitivity analysis by varying the gene filtering p-value threshold. (a) and (b) correspond 
to using p<0.05 as threshold (239 genes); (c) and (d) correspond to using p<0.1 as threshold (349 
genes). The genotype baseline (no NMF) RMSEs are 4.87 (4.63) for longitudinal strain and 1.56 
(1.50) for septal e’ velocity under p-value thresh-old 0.1 (0.05). Abbreviation: root-mean-square 
error (RMSE) 
